Challenges in the Treatment of Vasomotor Symptoms: Update in Non-Hormonal Strategies by Belardo Maria Alejandra in Open Access Journal of Reproductive System and Sexual Disorders (OAJRSD) in Lupinepublishers
Perimenopause
and menopause per se significantly impacts on women quality of life (QoL),
especially due to vasomotor symptoms (VMS); their duration is uncertain, and
often long. Although menopause hormone therapy (MHT) is the most effective
treatment for climacteric symptoms as a whole, its use is contraindicated in
some cases. Therefore, it is mandatory that different treatment approaches be
offered to women for whom hormone therapy is contraindicated. As for treatment
selection, there are a wide range of nonhormonal options, both pharmacological
and nonpharmacological. These options include alternative or natural therapies
(isoflavones and Cimicifuga Racemosa), lifestyle modifications and
complementary therapies. Regarding pharmacological strategies the literature
review shows that serotonin-norepinephrine reuptake inhibitors (SNRIs),
selective serotonin reuptake inhibitors (SSRIs), antihypertensives and
anticonvulsants, decrease the intensity and frequency of VMS, proving a
clinically significant improvement.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.